Sol-Gel Technologies Ltd. Ordinary Shares
SLGLSol-Gel Technologies Ltd. is a specialty pharmaceutical company focused on developing and commercializing innovative eye health products. Utilizing its proprietary sol-gel drug delivery platform, the company aims to enhance the effectiveness and convenience of treatments for various ocular conditions. Sol-Gel collaborates with other pharmaceutical firms and healthcare providers to bring advanced eye care solutions to market.
Company News
Over 22 pharmaceutical companies are developing new drugs for basal cell neoplasms, with promising therapies targeting various molecular pathways and showing potential in clinical trials.
Sol-Gel Technologies completed patient enrollment for Phase-3 clinical trial of SGT-610 for Gorlin Syndrome, sold U.S. rights to EPSOLAY and TWYNEO to Mayne Pharma for $16 million, and reported a net income of $11.6 million in Q2 2025.
Sol-Gel Technologies reported financial results for Q2 2024, including a net income of $1.9 million. The company provided updates on its pipeline, including the ongoing Phase 3 trial for SGT-610 in Gorlin Syndrome and the proof-of-concept study for SGT-210 in Darier disease. Sol-Gel also announced licensing agreements for its approved products TW...
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
